Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis

被引：0
|
作者：
Lei Wen
Junjie Zhen
Changguo Shan
Mingyao Lai
Weiping Hong
Hui Wang
Mingting Ye
Yanying Yang
Shaoqun Li
Zhaoming Zhou
Jiangfen Zhou
Qingjun Hu
Juan Li
Xuwei Tian
Longhua Chen
Linbo Cai
Zhanhong Xie
Cheng Zhou
机构：
[1] Guangdong Sanjiu Brain Hospital,Department of Oncology
[2] The First People’s Hospital of Kashi Prefecture,Department of Radiation Oncology
[3] Southern Medical University,Department of Radiation Oncology, Nanfang Hospital
[4] The First Affiliated Hospital of Guangzhou Medical University,State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute for Respiratory Health
来源：
European Journal of Medical Research | / 28卷
关键词：
Osimertinib; EGFR; NSCLC; Leptomeningeal metastases (LM); Efficacy; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Efficacy of Dacomitinib in EGFR TKI Refractory Metastatic Non-Small Cell Lung Cancer (EGFR Mutant) with Leptomeningeal Metastases
    Chan, D.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S627 - S627
  • [22] Osimertinib for EGFR-mutant non-small cell lung cancer: place in therapy and future perspectives
    Ricciuti, Biagio
    JOURNAL OF THORACIC DISEASE, 2019, 11 : S249 - S252
  • [23] Weight loss in patients on osimertinib for metastatic EGFR-mutant non-small cell lung cancer
    Chen, Lanyi Nora
    Ma, Xin
    Herzberg, Benjamin
    Henick, Brian S.
    Biswas, Anup K.
    Acharyya, Swarnali
    Shu, Catherine A.
    ONCOLOGIST, 2024,
  • [24] Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada
    Ezeife, Doreen A.
    Kirk, Veronica
    Chew, Derek S.
    Nixon, Nancy A.
    Lee, Roy
    Le, Lisa W.
    Chan, Kelvin K. -W.
    Leighl, Natasha B.
    LUNG CANCER, 2018, 125 : 1 - 7
  • [25] Phase I study of high dose gefitinib in patients with leptomeningeal metastases from EGFR-mutant non-small cell lung cancer
    Jackman, David M.
    Kesari, Santosh
    Cioffredi, Leigh-Anne
    Sequist, Lecia V.
    Rabin, Michael S.
    Lynch, Thomas J.
    Marcoux, J. P.
    Johnson, Bruce E.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S685 - S685
  • [26] Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
    Kim, Youjin
    Lee, Se-Hoon
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    Sun, Jong-Mu
    CANCER RESEARCH AND TREATMENT, 2019, 51 (02): : 502 - 509
  • [27] Efficacy and safety of immunotherapy in EGFR-mutant advanced non-small cell lung cancer: A retrospective study
    Tu, Tingting
    Li, Yang
    Liu, Ying
    Jiang, Lifeng
    ASIAN JOURNAL OF SURGERY, 2023, 46 (08) : 3275 - 3277
  • [28] Cardiac Events and Survival in Patients With EGFR-Mutant Non-Small Cell Lung Cancer Treated With Osimertinib
    Lin, Chien-Yu
    Chang, Wei-Ting
    Su, Po-Lan
    Kuo, Chin-Wei
    Yang, Jen
    Lin, Chien-Chung
    Lin, Sheng-Hsiang
    JAMA NETWORK OPEN, 2024, 7 (12)
  • [29] Acquired BRAF gene fusions in Osimertinib resistant EGFR-mutant non-small cell lung cancer
    Rosell, Rafael
    Gonzalez-Cao, Maria
    Codony-Servat, Jordi
    Molina-Vila, Miguel Angel
    Mayo de las Casas, Clara
    Ito, Masaoki
    TRANSLATIONAL CANCER RESEARCH, 2023, 12 (03) : 456 - 460
  • [30] Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors
    Saboundji, Karima
    Auliac, Jean-Bernard
    Perol, Maurice
    Francois, Geraldine
    Janicot, Henri
    Marcq, Marie
    Dubos-Arvis, Catherine
    Renault, Aldo
    Guisier, Florian
    Odier, Luc
    Gervais, Radj
    Chouaid, Christos
    TARGETED ONCOLOGY, 2018, 13 (04) : 501 - 507
12345